A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

• Participants who have had a diagnosis of type 2 diabetes mellitus before screening

• Participants who have been taking SU (Glibenclamide, Gliclazide, Glimepiride), BG,TZD, a-GI or glinides monotherapy for at least 3 months before screening and have beenon a stable dose for at least 8 weeks before screening

• Participants must have a qualifying HbA1c value of 7.0% to 11.0% at screening

• Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per metersquared (kg/m^2)

Exclusion Criteria:

• Participants who have a diagnosis of type 1 diabetes

• Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog within the 3 months before screening

• Participants who are currently taking insulin or have had previous insulin treatmentwithin the 3 months before screening

• Participants who have obvious clinical signs or symptoms of pancreatitis, a history ofchronic pancreatitis, or acute pancreatitis at screening, as determined by theinvestigator. Participants who have a serum amylase concentration ≥3 times the upperlimit of the reference range and/or a serum lipase concentration ≥2 times the upperlimit of the reference range, as determined by the central laboratory at screening

• Participants who have self or family history of medullary C-cell hyperplasia, focalhyperplasia, or medullary thyroid carcinoma (MTC)